Core Viewpoint - The Chinese government will ban the production of mercury thermometers and sphygmomanometers starting January 1, 2026, marking the end of mercury-based medical devices in the market [1]. Company Impact - Companies such as Yuyue Medical (002223.SZ), Jiuan Medical (002432.SZ), and Kefu Medical (301078.SZ) are currently selling mercury thermometers and sphygmomanometers, but their impact from the ban is expected to be minimal as they primarily focus on electronic products [1]. - Yuyue Medical stated that the volume of mercury-based products in their business is very small, with a major focus on electronic devices [1]. - Jiuan Medical indicated that they are not traditional manufacturers of thermometers and that their main revenue source comes from reagent kits, particularly in the U.S. market [1]. Market Trends - There has been a noticeable increase in demand for mercury thermometers on e-commerce platforms, leading to stock shortages, while electronic and glass thermometers remain available [2]. - In physical pharmacies, staff reported that mercury thermometers are selling out quickly, with many customers still preferring them despite the availability of electronic alternatives [4]. - The price of electronic thermometers and infrared thermometers is significantly higher, often exceeding 100 yuan, compared to the low price of mercury thermometers, which can be as low as 6.1 yuan [4]. Industry Response - Some medical enterprises have already stopped using mercury thermometers in anticipation of the ban and are transitioning to compliant products [5]. - Pharmacies have not yet received official notifications regarding the prohibition of selling mercury thermometers, indicating a potential lag in industry compliance [5].

Core Viewpoint - The Chinese government will ban the production of mercury-containing thermometers and blood pressure monitors starting January 1, 2026, marking the end of mercury thermometers in the market [1]. Company Impact - Companies such as Yuyue Medical (002223.SZ) and Jiuan Medical (002432.SZ) have indicated that the impact of this ban on their business will be minimal, as they primarily focus on electronic products and have a very small volume of mercury thermometer and blood pressure monitor sales [1]. - Jiuan Medical stated that it is not a traditional thermometer manufacturer and that its main revenue source comes from reagent kits, particularly in the U.S. market [1]. Market Observations - There has been a noticeable increase in demand for mercury thermometers on e-commerce platforms, leading to stock shortages, while electronic and glass thermometers are more readily available [2]. - In physical pharmacies, staff reported that mercury thermometers are selling out quickly, with many customers still preferring them despite the availability of electronic alternatives [4][6]. Transition to Alternatives - Pharmacies are increasingly stocking electronic and infrared thermometers, which are priced significantly higher than mercury thermometers, indicating a shift in consumer preference [4][6]. - Medical companies are preparing to transition away from mercury products in compliance with government regulations, although some have not yet received formal notifications regarding the sales ban [6].

Core Viewpoint - The Chinese government will ban the production of mercury-containing thermometers and blood pressure monitors starting January 1, 2026, marking the end of mercury thermometers in the market [1]. Company Impact - Companies such as Yuyue Medical (002223.SZ) and Jiuan Medical (002432.SZ) have indicated that the impact of this ban on their business will be minimal, as they primarily focus on electronic products and have a very small volume of mercury thermometer and blood pressure monitor sales [1][5]. - Jiuan Medical stated that their main revenue source comes from reagent kits, particularly in the U.S. market, and they are not traditional manufacturers of thermometers [1]. Market Observations - There has been a noticeable increase in demand for mercury thermometers on e-commerce platforms, leading to stock shortages, while electronic and glass thermometers are more readily available [2]. - In physical pharmacies, staff reported that they have sold out of mercury thermometers due to increased demand, especially during the flu season, but they still offer electronic and infrared thermometers at significantly higher prices [4]. Industry Transition - Some medical companies have already begun transitioning away from mercury thermometers in anticipation of the ban, although they have not received formal notifications regarding the prohibition of sales [5]. - The market is expected to shift towards electronic and infrared thermometers, which are perceived as more convenient, especially for families with young children [4].

Market Performance - The Tianjin Free Trade Zone concept index declined by 2.31%, ranking among the top declines in the concept sector as of the market close on December 9 [1] - Within the sector, Hengyin Technology, Haitai Development, and Tianbao Infrastructure experienced significant declines, while only two stocks, Guifaxiang and Tianjin Pulin, saw price increases of 1.17% and 0.77% respectively [1] Concept Sector Overview - The top-performing concept sectors included Co-packaged Optics (CPO) with a gain of 1.64%, and Hainan Free Trade Zone with a decline of 3.33% [2] - The Tianjin Free Trade Zone concept was among the sectors with the largest decline, alongside other sectors such as Metal Lead and Metal Zinc [2] Capital Flow Analysis - The Tianjin Free Trade Zone concept saw a net outflow of 170 million yuan, with 10 stocks experiencing net outflows, and 5 stocks seeing outflows exceeding 10 million yuan [2] - Hengyin Technology led the outflows with a net outflow of 83.04 million yuan, followed by Jiuan Medical and Tianbao Infrastructure with outflows of 27.93 million yuan and 24.50 million yuan respectively [2] - Conversely, the stocks with the highest net inflows included Haitai Development, Jinyin Development, and Guifaxiang, with inflows of 14.12 million yuan, 4.71 million yuan, and 1.10 million yuan respectively [2][3]

Group 1 - The company, Jiuan Medical, announced a share buyback plan, repurchasing approximately 10.57 million shares, which represents 2.27% of its total share capital, with a total expenditure of about 425 million RMB [1][1][1] - The highest transaction price during the buyback was 41.6 RMB per share, while the lowest was approximately 39.60 RMB per share [1][1][1] - As of the report, Jiuan Medical's market capitalization stands at 19.3 billion RMB [1][1][1] Group 2 - For the first half of 2025, Jiuan Medical's revenue composition is as follows: 87.74% from medical devices, 6.57% from internet medical products and services, 5.03% from retail business, and 0.66% from other industries [1][1][1]

北京商报讯12月1日，九安医疗发布公告称，截至11月30日，公司通过股份回购专用证券账户以集中竞 价方式累计回购公司股份数1056.63万股，占公司目前总股本的2.27%，最高成交价为41.6元/股，最低成 交价为39.598元/股，支付的总金额为4.25亿元（不含交易费用）。 据公告，九安医疗于10月13日召开的第六届董事会第二十七次会议，审议并通过了《关于公司回购股份 方案的议案》，本次回购资金来源为公司自有资金及回购专项贷资金，回购的资金总额不低于3亿元 （含）且不超过6亿元（含），回购股份的价格为不超过53.5元/股（含），具体回购数量以回购期限届 满时实际回购的股份数量为准。 （文章来源：北京商报） ...

本次会议审议的议案由公司第六届董事会第二十九次会议、第六届监事会 第二十三次会议审议通过后提交，程序合法，资料完备。上述议案中的"第 1.0 0 项"为特别决议事项，需经出席会议的股东（包括股东代理人）所持表决权 的三分之二以上（含）通过。 补充后： 本次会议审议的议案由公司第六届董事会第二十九次会议、第六届监事会 第二十三次会议审议通过后提交，程序合法，资料完备。上述议案中的"第 1.0 0 项、4.01 项、4.02 项"为特别决议事项，需经出席会议的股东（包括股东代 理人）所持表决权的三分之二以上（含）通过。 证券代码：002432 证券简称：九安医疗 公告编号：2025-097 天津九安医疗电子股份有限公司 关于召开2025年第四次临时股东大会通知的补充公告 本公司及董事会全体成员保证信息披露的内容真实、准确和 完整，没有虚假记载、误导性陈述或重大遗漏。 天津九安医疗电子股份有限公司（以下简称"公司"）于 2025 年 11 月 29 日 在巨潮资讯网（www.cninfo.com.cn）披露了《天津九安医疗电子股份有限公 司关于召开 2025 年第四次临时股东大会的通知》（公告编号：2025-094 ...

格隆汇12月1日丨九安医疗(002432.SZ)公布，截至2025年11月30日，公司通过股份回购专用证券账户以 集中竞价方式累计回购公司股份数10,566,301股，占公司目前总股本的2.27%，最高成交价为41.60元/ 股，最低成交价为39.598元/股，支付的总金额为人民币425,079,896.66元（不含交易费用）。本次回购 符合相关法律法规的要求，符合既定的回购股份方案。 ...

证券代码：002432 证券简称：九安医疗 公告编号：2025-096 天津九安医疗电子股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和 完整，没有虚假记载、误导性陈述或重大遗漏。 天津九安医疗电子股份有限公司（以下简称"公司"）于2025年10月13日召 开了第六届董事会第二十七次会议，审议并通过了《关于公司回购股份方案的议 案》。本次回购资金来源为公司自有资金及回购专项贷资金，回购的资金总额不 低于3亿元人民币（含）且不超过6亿元人民币（含），回购股份的价格为不超过 人民币53.5元/股（含），具体回购数量以回购期限届满时实际回购的股份数量为 准。具体回购方案详见公司2025年10月14日在《证券时报》和巨潮资讯网 （http://www.cninfo.com.cn）披露的《关于回购公司股份方案暨取得股票回购专 项贷款承诺函的公告》（公告编号：2025-075）。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9号—回购股份》等相关规定，公司在回购期间应当在每个月的前3个交易日内公 告截至上月末的回购进展情况。现将公司回购股份进展情况公告 ...

九安医疗12月1日公告，公司于2025年10月13日召开了第六届董事会第二十七次会议，审议并通过了 《关于公司回购股份方案的议案》。本次回购资金来源为公司自有资金及回购专项贷资金，回购的资金 总额不低于3亿元（含）且不超过6亿元（含），回购股份的价格为不超过53.5元/股（含）。截至2025 年11月30日，公司累计回购1056.63万股，占公司总股本的2.27%，回购价格区间为39.598元/股至41.6元/ 股，累计使用资金4.25亿元（不含交易费用）。 ...